Immunome, Inc. (IMNM)
NASDAQ:IMNM
Want to see IMNM full AI Analyst Report?
Im-1617
Colorectal Cancer, Non-small Cell Lung Cancer, Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer
Phase I
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
May 05, 2026
―
Varegacestat, Moxifloxacin 400 Mg
Healthy Volunteer
Phase I
Completed
A Cardiac Liability Study of Varegacestat in Healthy Participants
Feb 25, 2025
―
Varegacestat
Healthy Volunteer
Phase I
Completed
A Phase 1 Mass Balance Study of Varegacestat
Feb 05, 2025
―
Varegacestat
Hepatic Impairment (Hi), Healthy Volunteer
Phase I
Active Not Recruiting
A Varegacestat Hepatic Impairment Study
Jan 24, 2025
―
Varegacestat, Itraconazole
Healthy Volunteer
Phase I
Completed
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
Nov 04, 2024
―
Al102
Desmoid, Desmoid Tumor
Phase II/III
Active Not Recruiting
A Study of AL102 in Patients With Progressing Desmoid Tumors
Apr 23, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immunome, Inc. (IMNM) have in its pipeline
IMNM is currently developing the following drugs: Im-1617, Varegacestat, Moxifloxacin 400 Mg, Varegacestat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.